A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs FPA 144 (Primary)
- Indications Bladder cancer; Gastric cancer; Lymphoma; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Five Prime Therapeutics
- 21 Nov 2017 Planned number of patients changed from 210 to 100.
- 21 Nov 2017 Planned End Date changed from 1 May 2019 to 1 Nov 2019.
- 21 Nov 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History